CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Afamelanotide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04425746
NCT04425746Phase 2Completed
CompareCT.gov

A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 (Afamelanotide) as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium

Clinuvel Pharmaceuticals Limited·interventional·Posted Jun 11, 2020·Updated Oct 1, 2021

In Brief

A Phase 2 clinical trial evaluating Afamelanotide and Placebo for Patients Undergoing Photodynamic Therapy Using Porfimer Sodium. Completed, enrolled 16 participants.

Detailed Summary

The purpose of this study was to evaluate the safety and efficacy of afamelanotide (previously developed as CUV1647) as adjunctive therapy in patients undergoing photodynamic therapy using porfimer sodium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients Undergoing Photodynamic Therapy Using Porfimer Sodium
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 11, 2020
Enrollment StartAug 5, 2008
Primary CompletionMay 28, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.1 years ago

Interventions

Afamelanotidedrug

Placebodrug